Skip to main content

Daily Sepsis Research Analysis

3 papers

A large pragmatic pediatric RCT found that a procalcitonin-guided algorithm did not shorten intravenous antibiotic duration and was non-inferior for safety compared with usual care. A single-center cohort linked early changes in the urea-to-creatinine ratio to rapid muscle loss in sepsis. A meta-analysis suggests aspirin may reduce mortality and ICU stay in elderly sepsis patients, but findings are likely confounded and call for RCTs.

Summary

A large pragmatic pediatric RCT found that a procalcitonin-guided algorithm did not shorten intravenous antibiotic duration and was non-inferior for safety compared with usual care. A single-center cohort linked early changes in the urea-to-creatinine ratio to rapid muscle loss in sepsis. A meta-analysis suggests aspirin may reduce mortality and ICU stay in elderly sepsis patients, but findings are likely confounded and call for RCTs.

Research Themes

  • Antibiotic stewardship and biomarker-guided therapy in pediatric infections
  • Metabolic biomarkers predicting rapid muscle loss in sepsis
  • Adjunctive antiplatelet therapy signals in elderly sepsis (hypothesis-generating)

Selected Articles

1. Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trial.

7.6Level IRCTThe Lancet. Child & adolescent health · 2025PMID: 39798581

In a multicentre pragmatic RCT of 1,949 hospitalized children, a procalcitonin-guided algorithm did not shorten the duration of IV antibiotics versus usual care and was non-inferior for safety. The findings argue against routine use of procalcitonin-guided algorithms where robust pediatric stewardship is in place.

Impact: This is the largest pragmatic pediatric RCT testing procalcitonin-guided therapy against contemporary stewardship, delivering definitive negative evidence that can immediately inform guidelines and policy.

Clinical Implications: Do not implement procalcitonin-guided algorithms solely to reduce IV antibiotic duration in pediatric inpatients where strong stewardship exists; maintain current stewardship-based decision-making.

Key Findings

  • No reduction in IV antibiotic duration: median 96.0 h (PCT) vs 99.7 h (usual care); HR 0.96 (95% CI 0.87–1.05).
  • Safety was non-inferior: composite adverse events in 9% vs 9%; adjusted risk difference −0.81% (95% CI upper bound 1.11, below 5% margin).
  • Pragmatic, multicentre RCT across 15 hospitals randomizing 1,949 children using minimisation with age and site.

Methodological Strengths

  • Pragmatic multicentre randomized design with clear co-primary endpoints (superiority and non-inferiority).
  • Minimisation randomisation and trial registration with predefined non-inferiority margin.

Limitations

  • Open-label design could influence clinician behavior despite objective primary outcome.
  • Findings reflect UK settings with strong stewardship and may not generalize to regions with different practices; focus on IV duration may not capture total antibiotic exposure.

Future Directions: Evaluate procalcitonin or combined biomarker algorithms in settings with less mature stewardship, and identify subgroups (e.g., severe sepsis, immunocompromised) where biomarker guidance may add value.

2. Early urea-to-creatinine ratio to predict rapid muscle loss in critically ill patients with sepsis: a single-center retrospective observational study.

5.25Level IIICohortBMC anesthesiology · 2025PMID: 39799321

In 482 adults with sepsis, early changes in the urea-to-creatinine ratio (ΔUCR) independently predicted rapid muscle loss defined by CT-derived L3 muscle area decline >2% per day. ΔUCR achieved an AUC of 0.76 with a threshold of 19.4 µmol urea/µmol creatinine, suggesting a practical early warning biomarker.

Impact: Links a widely available laboratory ratio to objective CT-based sarcopenia metrics in ICU sepsis, providing a feasible tool to triage patients for early nutrition and rehabilitation.

Clinical Implications: Serially monitor UCR changes in ICU sepsis to flag patients at risk of rapid muscle loss and trigger early nutrition, mobilization, and potential anabolic strategies; consider confirmatory imaging when ΔUCR exceeds threshold.

Key Findings

  • Rapid muscle loss occurred in 29.2% (141/482) of septic ICU patients.
  • ΔUCR independently associated with rapid muscle loss: OR 1.02 (95% CI 1.01–1.02).
  • Predictive performance for ΔUCR: AUC 0.76 (95% CI 0.68–0.83); threshold 19.4 µmol urea/µmol creatinine.

Methodological Strengths

  • Objective quantification of muscle loss using CT-derived L3 cross-sectional area.
  • Multivariable logistic regression with threshold determination and ROC analysis.

Limitations

  • Single-center retrospective design with potential residual confounding and selection bias.
  • UCR is influenced by renal function and catabolic state; generalizability beyond the studied ICU population is uncertain.

Future Directions: Prospectively validate ΔUCR thresholds across centers, integrate with functional measures (e.g., ultrasound, handgrip), and test whether ΔUCR-guided interventions mitigate ICU-acquired weakness.

3. A meta-analysis of the efficacy and safety of aspirin in the treatment of elderly patients with sepsis.

4.55Level IIMeta-analysisPakistan journal of pharmaceutical sciences · 2024PMID: 39799452

Across 12 studies including 136,931 elderly sepsis patients, aspirin use was associated with lower ICU, in-hospital, 30-day, and 90-day mortality, fewer bleeding events, and shorter ICU stay, without affecting organ failure incidence. Given likely observational designs and confounding, the findings are hypothesis-generating and warrant randomized trials.

Impact: The meta-analysis aggregates a large elderly sepsis population, signaling potential mortality benefit and acceptable safety with aspirin, which could redirect research toward mechanistic and randomized evaluations.

Clinical Implications: Do not change practice based on these results alone; if aspirin is used for other indications in elderly sepsis, clinicians should weigh bleeding risk and monitor closely. Prioritize enrollment in randomized trials evaluating low-dose aspirin as adjunctive therapy.

Key Findings

  • Included 12 studies with a total of 136,931 elderly sepsis patients.
  • Aspirin use associated with reduced ICU, in-hospital, 30-day, and 90-day mortality.
  • Associated with fewer bleeding events and shorter ICU length of stay; no improvement in organ failure incidence.

Methodological Strengths

  • Large aggregated sample size across multiple databases with meta-analytic synthesis.
  • Comprehensive literature search across PubMed, Embase, Cochrane Library, Web of Science, and Medline.

Limitations

  • Likely dominated by observational studies with residual confounding and selection bias; risk-of-bias and heterogeneity not detailed.
  • Counterintuitive reduction in bleeding events with aspirin raises concerns about confounding and outcome definitions.

Future Directions: Conduct adequately powered randomized controlled trials of low-dose aspirin in elderly sepsis, with standardized bleeding definitions and organ dysfunction endpoints; explore mechanistic platelet–immune interactions.